Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2015 Sep 13;3(11):866–875. doi: 10.1016/S2213-8587(15)00291-0

Figure 2.

Figure 2

Cumulative incidence of diabetes by treatment group among the 2776 DPPOS participants. The DPP and DPPOS periods, and the overlap between them, are indicated. Over the entire study, the incidence rates for participants were 7.0%, 5.7% and 5.2% per year for placebo, metformin and lifestyle, respectively, 27% and 18% lower for lifestyle and metformin vs. placebo, respectively (p<0.0001 and p= 0.001). The difference between lifestyle and metformin was not significant (p=0.10). The number at risk at each time point is listed by treatment group.